Skip to content

Study · Randomized controlled trial · 1993

9 results

Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration.

Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R

Acta paediatrica (Oslo, Norway : 1992). Supplement1 Mar 1993Cited by 5 (Europe PMC)

PMID8329825 (opens in a new tab)DOI10.1111/j.1651-2227.1993.tb12827.x (opens in a new tab)PepBankPUB-08329825
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In healthy men, the lowest intravenous dose tested, 0.25 microgram/kg, of GHRH(1-29)-NH2 elicited significant GH release.

    In plain wordsIn healthy men, the lowest injected dose of GHRH(1-29)-NH2 tested, 0.25 microgram/kg, caused a clear release of growth hormone.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH release after 0.25 microgram/kg intravenous GHRH(1-29)-NH2
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.25 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Intravenous injection of the lowest dose tested, 0.25 microgram/kg body weight, elicited significant release of growth hormone (GH).
    1 context sentence
    Summary · context
    The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.
  2. 02HumanRandomized controlled trialActivity measurement

    In healthy men, maximal GH release after intravenous GHRH(1-29)-NH2 was obtained with a dose of 1-2 micrograms/kg.

    In plain wordsIn healthy men, injected GHRH(1-29)-NH2 gave its largest growth hormone release at a dose of 1-2 micrograms/kg.

    Peptide
    Sermorelin
    Outcome
    IncreaseMaximal GH release after intravenous GHRH(1-29)-NH2
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1-2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    Mean GH peak
    ≈ 90 mU/l
    1-2 micrograms/kg intravenous

    Source sentences

    Summary
    Maximal release (mean GH peaks of about 90 mU/l) was obtained with a dose of 1-2 micrograms/kg.
    1 context sentence
    Summary · context
    The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy men, GHRH(1-29)-NH2 was rapidly eliminated after intravenous injection.

    In plain wordsIn healthy men, the body cleared injected GHRH(1-29)-NH2 rapidly.

    Peptide
    Sermorelin
    Outcome
    Not applicableElimination after intravenous injection
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    GHRH(1-29)-NH2 was rapidly eliminated after intravenous injection
    1 context sentence
    Summary · context
    The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.
  4. 04HumanRandomized controlled trialActivity measurement

    In healthy men, GH levels stayed elevated for about 3 hours after intravenous GHRH(1-29)-NH2.

    In plain wordsIn healthy men, growth hormone stayed raised for about 3 hours after an injection of GHRH(1-29)-NH2.

    Peptide
    Sermorelin
    Outcome
    IncreaseDuration of elevated GH after intravenous GHRH(1-29)-NH2
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Duration of elevated GH
    ≈ 3 hours
    intravenous

    Source sentences

    Summary
    GH levels were elevated for about 3 hours.
    1 context sentence
    Summary · context
    The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In healthy men, absorption of GHRH(1-29)-NH2 through the nasal mucosa was low, with a bioavailability of only 3-5%.

    In plain wordsIn healthy men, little GHRH(1-29)-NH2 passed through the nose lining into the body: only 3-5%.

    Peptide
    Sermorelin
    Outcome
    Not applicableIntranasal bioavailability
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Bioavailability
    3 to 5%
    intranasal

    Source sentences

    Summary
    Absorption of GHRH(1-29)-NH2 through the nasal mucosa was found to be low, and the bioavailability was only 3-5%.
    1 context sentence
    Summary · context
    The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.
  6. 06HumanRandomized controlled trialActivity measurement

    In healthy men, intranasal GHRH(1-29)-NH2 released GH in a dose-dependent way.

    In plain wordsIn healthy men, higher nose-spray doses of GHRH(1-29)-NH2 released more growth hormone.

    Peptide
    Sermorelin
    Outcome
    IncreaseDose-dependent GH release after intranasal GHRH(1-29)-NH2
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    There was a dose-dependent release of GH after intranasal administration of GHRH(1-29)-NH2
    1 context sentence
    Summary · context
    The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.
  7. 07HumanRandomized controlled trialActivity measurement

    In healthy men, the maximal GH response to intranasal GHRH(1-29)-NH2 came at about 50 micrograms/kg, approximately as potent as 1 microgram/kg injected intravenously.

    In plain wordsIn healthy men, about 50 micrograms/kg through the nose gave a growth hormone response similar to 1 microgram/kg by injection.

    Peptide
    Sermorelin
    Outcome
    Not applicableIntranasal dose for maximal GH response compared with intravenous
    Study

    n: not reported in source

    Comparator
    1 microgram/kg intravenous
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    about 50 micrograms/kg · intranasalAs given in this study (human).

    Measurements

    Dose for maximal GH response
    ≈ 50 micrograms/kg
    intranasal

    Source sentences

    Summary
    with the maximal response obtained with about 50 micrograms/kg; this dose was approximately as potent as 1 microgram/kg injected intravenously.
    1 context sentence
    Summary · context
    The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.
  8. 08HumanRandomized controlled trialActivity measurement

    In healthy men, the GH response after repeated intranasal GHRH(1-29)-NH2 was sustained.

    In plain wordsIn healthy men, the growth hormone response to repeated nose-spray doses of GHRH(1-29)-NH2 did not fade.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH response to repeated intranasal GHRH(1-29)-NH2
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    The GH response after repeated intranasal administration of GHRH(1-29)-NH2 was sustained
    1 context sentence
    Summary · context
    The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.
  9. 09HumanRandomized controlled trialActivity measurement

    In healthy men, there was no suppression of GH secretion during the night after GHRH(1-29)-NH2 was given three times intranasally during the day.

    In plain wordsIn healthy men, three nose-spray doses of GHRH(1-29)-NH2 in one day did not suppress growth hormone release that night.

    Peptide
    Sermorelin
    Outcome
    No significant changeNocturnal GH secretion after three intranasal doses
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    three doses in one day · intranasalAs given in this study (human).

    Source sentences

    Summary
    there was no suppression of GH secretion during the night following a day when GHRH(1-29)-NH2 had been given three times intranasally.
    1 context sentence
    Summary · context
    The growth hormone-releasing hormone analogue GHRH(1-29)-NH2 was administered intravenously or intranasally to 30 healthy men aged 19-43 years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.